Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 248 results.
LastUpdate Updated on 19/04/2026 [07:16:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Results 150 to 175 of 248 nextPage  

MANIPULATING UHRF1 EXPRESSION IN HEPATOCYTES

Publication No.:  WO2026047621A1 05/03/2026
Applicant: 
NEW YORK UNIV IN ABU DHABI CORPORATION [AE]
WO_2026047621_A1

Absstract of: WO2026047621A1

Provided is a method that involves inhibiting expression of UHRF1 in liver cells of an individual. Inhibiting the expression of UHRF1 promotes an inhibition of reduction of bone density or an increase in bone density, or inhibition of weight gain or a reduction in adipose mass, or inhibition of development of gray hair or an increase in activity level, or a decrease in biological age or enhanced liver regeneration, or increased survival following partial hepatectomy, or a combination of such effects.

DPP3 BINDERS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION

Publication No.:  WO2026046968A1 05/03/2026
Applicant: 
4TEEN4 PHARMACEUTICALS GMBH [DE]
WO_2026046968_A1

Absstract of: WO2026046968A1

Subject of the invention are DPP3 binders for use in therapy or prevention of endothelial dysfunction in a patient wherein the level of Pro-Adrenomedullin or a fragment thereof in a sample of bodily fluid obtained from said patient is above a threshold, as well as methods of therapy guidance or therapy stratification or therapy monitoring of a treatment of a patient with a DPP3 binder, the methods comprising: providing a sample of bodily fluid of said patient; determining the level of Pro-Adrenomedullin or a fragment thereof in said sample; and comparing said level of Pro-Adrenomedullin or a fragment thereof to a threshold; wherein the level of Pro-Adrenomedullin or a fragment thereof in said sample being above said threshold is indicative that said patient requires treatment with a DPP3 binder, or wherein if said level of Pro-Adrenomedullin or a fragment thereof in said sample is above said threshold, said patient is treated with a DPP3 binder.

CIRCULATING BIOMARKER LEVELS FOR DIAGNOSIS AND RISK-STRATIFICATION OF TRAUMATIC BRAIN INJURY

Publication No.:  US20260063646A1 05/03/2026
Applicant: 
BRAINBOX SOLUTIONS INC [US]
US_20260063646_PA

Absstract of: US20260063646A1

Methods, compositions and kits useful in the diagnosis, prognosis and/or assessment of brain injuries and risk for brain injuries, such as hemorrhage, are based upon detection of certain biomarkers.

Anticuerpos anti-proteína a-beta, métodos y usos de estos

Publication No.:  CO2026000998A2 05/03/2026
Applicant: 
F HOFFMANN LA ROCHE AG [CH]
F. HOFFMANN-LA ROCHE AG
CN_121620524_PA

Absstract of: AU2024322991A1

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA IN ALZHEIMER'S AND OTHER DISEASES

Publication No.:  AU2024325238A1 05/03/2026
Applicant: 
LVIS REGAIN LP
LVIS-REGAIN LP
AU_2024325238_PA

Absstract of: AU2024325238A1

Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.

Methods and Reagents for Toxoplasma Infection Diagnosis

Publication No.:  US20260063633A1 05/03/2026
Applicant: 
MCLEOD RIMA [US]
LIMONNE DENIS [FR]
PEYRON FRANCOIS [FR]
EL BISSATI KAMAL [US]
LYKINS JOE [US]
WALLON MARTINE [FR]
GOMEZ MARIN JORGE [CO]
ZHOU YING [US]
US_20260063633_PA

Absstract of: US20260063633A1

0000 Point-of-care (POC) testing for T. gondii infection can potentially address cost concerns and lead to better clinical outcomes through improved access to screening. This disclosure provides methods and compositions for whole blood POC testing to identify T. gondii infection with high sensitivity and specificity, obviating the need for venipuncture and sample processing infrastructure, making it an efficient, low-cost POC test.

COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER USING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)

Publication No.:  WO2026050116A1 05/03/2026
Applicant: 
UNIV COLORADO REGENTS [US]
WO_2026050116_PA

Absstract of: WO2026050116A1

Embodiments of the instant disclosure relate to intervention and/or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

Aptamere, aptamerbasierte Sensoren und Verfahren für den Nachweis von Neurofilament Light

Publication No.:  DE102024124992A1 05/03/2026
Applicant: 
FORSCHUNGSZENTRUM JUELICH GMBH [DE]
DE_102024124992_PA

Absstract of: DE102024124992A1

Die vorliegende Erfindung betrifft Aptamere, die an Neurofilament Light binden, Biosensoren, Verwendungen der Aptamere, Verfahren zum Nachweis von Neurofilament Light.

STEREOINVERSION METHOD FOR CELL-TYPE SPECIFIC LABELLING OF AMINO-ACIDS AND THEIR METABOLITES

Publication No.:  WO2026047133A2 05/03/2026
Applicant: 
THE FRANCIS CRICK INSTITUTE LTD [GB]
WO_2026047133_A2

Absstract of: WO2026047133A2

The invention relates to methods of tracking the movement of an amino acid of interest or a metabolite thereof in a eukaryotic multicellular structure, methods of diagnosis and screening related thereto, and nucleic acids encoding amino-acid stereo- isomerase for use therein.

Methods for Assaying a Bodily Sample of a Subject

Publication No.:  US20260063642A1 05/03/2026
Applicant: 
AGENT S A S [FR]
US_20260063642_PA

Absstract of: US20260063642A1

0000 In an aspect, the present disclosure provides a method comprising: (a) obtaining a bodily sample from a subject; and (b) assaying the bodily sample to determine a level of analytes in the sample, wherein the analytes comprise nucleic acids, proteins, or metabolites.

COMPOSITION FOR MICROGLIAL REJUVENATION

Publication No.:  WO2026049217A1 05/03/2026
Applicant: 
UNIV CHA IND ACAD COOP FOUND [KR]
SUNGKWANG MEDICAL FOUND [KR]
\uCC28\uC758\uACFC\uD559\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8
\uC758\uB8CC\uBC95\uC778 \uC131\uAD11\uC758\uB8CC\uC7AC\uB2E8
WO_2026049217_PA

Absstract of: WO2026049217A1

A composition for microglial rejuvenation according to an aspect, in which the composition comprises, as an active ingredient, an expression of an ACE protein or a gene inhibitor encoding same, rejuvenates microglia rather than suppresses neuroinflammatory responses in order to treat, prevent, or alleviate brain aging-related diseases. Accordingly, the composition is expected to be widely used in the treatment of most brain aging-related diseases for which existing neuroinflammatory response suppression strategies have failed.

METHODS OF TREATING A COGNITIVE IMPAIRMENT

Publication No.:  AU2024345495A1 05/03/2026
Applicant: 
GRIFOLS WORLDWIDE OPERATIONS LTD
GRIFOLS WORLDWIDE OPERATIONS LIMITED
AU_2024345495_A1

Absstract of: AU2024345495A1

The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.

MAGNETIC FORMULATIONS FOR BIOMARKER SAMPLING AND ENHANCED DRUG DELIVERY

Publication No.:  US20260061081A1 05/03/2026
Applicant: 
ROCKET SCIENCE HEALTH CORP [CA]
Rocket Science Health Corp
US_20260061081_PA

Absstract of: US20260061081A1

The present disclosure describes formulations, methods, and devices tor biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.

CYCLOPROPANE-TAGGING METHOD FOR TRACKING FATTY ACID TRANSPORT BETWEEN CELLS AND TISSUES IN VIVO AND IN CELL CULTURE

Publication No.:  WO2026047150A1 05/03/2026
Applicant: 
THE FRANCIS CRICK INSTITUTE LTD [GB]
WO_2026047150_A1

Absstract of: WO2026047150A1

The invention relates to methods of tracking fatty acids and/or fatty acyl chains between an origin cell and one or more destination cells or locations in a multicellular structure, methods of diagnosis and screening related thereto, and nucleic acids encoding cyclopropane fatty acid synthase for use therein.

METHODS AND ASSAYS FOR MODULATING GENE TRANSCRIPTION BY MODULATING CONDENSATES

Publication No.:  KR20260030170A 05/03/2026
Applicant: 
화이트헤드인스티튜트포바이오메디칼리서치메사추세츠인스티튜트오브테크놀로지
KR_20260030170_PA

Absstract of: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

Biomarkers For A Systemic Lupus Erythematosus (SLE) Disease Activity Immune Index That Characterizes Disease Activity

Publication No.:  US20260063632A1 05/03/2026
Applicant: 
OKLAHOMA MED RES FOUND [US]
US_20260063632_PA

Absstract of: US20260063632A1

The present invention includes a method of characterizing disease activity in a systemic lupus erythematosus patient (SEE), comprising: obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, wherein the dataset comprises data representing the level of one or more biomarkers in the blood, serum, plasma or urine sample from each of (b) to (g); at least one innate serum or plasma mediator biomarker; at least one adaptive serum or plasma mediator; at least one chemokine/adhesion molecule biomarker; at least one soluble TNF superfamily biomarker; the inflammatory mediator biomarker SCF; at least one SLE-associated autoantibody specificity biomarker; and calculating a Lupus Disease Activity Immune.

Method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (IECT)

Publication No.:  US20260063648A1 05/03/2026
Applicant: 
PAM THERAGNOSTICS GMBH [DE]
US_20260063648_PA

Absstract of: US20260063648A1

0000 The present application is directed to a method for the prediction of a risk of side effects and/or prediction of the severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cells in the frame of an immune effector cell therapy (IECT), and/or for assessing an effect of a treatment of side effects in a cancer patient that has been treated with immune effector cells in the frame of an IECT, the method comprising the steps of a) determining the level of at least one endothelial dysfunction biomarker in a sample of bodily fluid of the patient, and b) correlating the level of the at least one endothelial dysfunction biomarker in the sample to the risk of the side effects and/or the severity of the side effects in the patient and/or to the effect of the treatment of the side effects in the patient. Further aspects relate to corresponding methods stratification and medicaments for use in corresponding treatment.

NOVEL METHOD

Publication No.:  WO2026047343A1 05/03/2026
Applicant: 
BABRAHAM INST [GB]
WO_2026047343_PA

Absstract of: WO2026047343A1

The present invention is directed to a method of identifying genomic nucleic acid regions associated with chromatin marks, genome binding proteins and/or genomic modifications, and the transcriptome in a sample, said method comprising in situ single step fragmentation and adapter sequence insertion using individual anti-chromatin mark, anti-genome binding protein and/or anti-genomic modification antibody-transposase-adapter complexes, each of said complexes comprising one or more antibodies specific for a chromatin mark, genome binding protein and/or genomic modification of interest with an indexed transposase-adapter sequence, and mRNA transcript capture and in situ reverse transcription. Also provided are methods of identifying chromatin marked, genome binding protein bound and/or modified genomic nucleic acid regions associated with a particular disease state and/or a particular state of developmental differentiation, as well as kits for performing the methods herein.

NANOPORE PEPTIDE PROFILING AND SEQUENCING BY HYDROLYSIS

Publication No.:  WO2026046058A1 05/03/2026
Applicant: 
NANJING UNIVERSITY [CN]
WO_2026046058_PA

Absstract of: WO2026046058A1

A method of characterizing a peptide using a nanopore incorporating at least one metal ion as a sensing moiety. A method of profiling or sequencing a polypeptide by fragmenting the polypeptide and then characterizing the fragments using a nanopore incorporating at least one metal ion as a sensing moiety.

多発性硬化症のETX依存性診断および療法

Publication No.:  JP2026507509A 04/03/2026
Applicant: 
コーネル・ユニバーシティー
JP_2026507509_PA

Absstract of: CA2106077A1

2106077 9216902 PCTABS00016 A data processing pension plan monitor (40) is directed specifically to the management and controlled access of pensionbacked credit (AC). This system permits pension plan participants to establish a line of credit (LOC), based on their vested interest in a sponsored pension plan (10). This LOC is thereafter systematically applied to a plurality of account (80, 90), each permitted selected credit card (90) and/or check writing privileges. The charges associated with the credit accessed are paid back to the pensioner, thereby retaining certain tax deferred privileges while permitting access to the accumulated funds.

스플라이싱 모니터링 방법

Publication No.:  KR20260028678A 04/03/2026
Applicant: 
레이지바이오텍피티와이리미티드
KR_20260028678_PA

Absstract of: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

SILICON NANOWIRE COMPOSITE AND MANUFACTURING METHOD THEREOF AND MEASUREMENT METHOD USING A SENSOR CONTAINING THE SAME

Publication No.:  KR20260028293A 04/03/2026
Applicant: 
가천대학교산학협력단
KR_20260028293_PA

Absstract of: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

A METHOD FOR A PREPARATION OF A MOLECULARLY-IMPRINTED-POLYMER (MIP) ELECTROCHEMICAL SENSOR FOR AN ELECTROCHEMICALLY INACTIVE ANALYTE DETECTION, A METHOD FOR USING SAID SENSOR AND SUCH A SENSOR

Publication No.:  EP4703717A1 04/03/2026
Applicant: 
TALLINN UNIV OF TECHNOLOGY [EE]
EP_4703717_PA

Absstract of: EP4703717A1

The invention relates to a method for a preparation of a molecularly-imprinted-polymer (MIP) electrochemical sensor for an electrochemically inactive analyte detection, a method for using said sensor and such a sensor, where a redox-active surface of the sensor is preferably made of a transition metal oxide, and more preferably ruthenium oxide (RuO2), wherein the redox-active surface is coated by a MIP layer, wherein the MIP layer comprises a plurality of analyte-selective cavities. Said sensor is comprising at least one electrode with an electrically conductive surface with a redox-active surface, preferably a transition metal oxide, and more preferably ruthenium oxide.

多発性硬化症疾患進行を予測するためのバイオマーカー

Publication No.:  JP2026035743A 04/03/2026
Applicant: 
オクターブバイオサイエンスインコーポレイテッド
JP_2026035743_PA

Absstract of: CA2106077A1

2106077 9216902 PCTABS00016 A data processing pension plan monitor (40) is directed specifically to the management and controlled access of pensionbacked credit (AC). This system permits pension plan participants to establish a line of credit (LOC), based on their vested interest in a sponsored pension plan (10). This LOC is thereafter systematically applied to a plurality of account (80, 90), each permitted selected credit card (90) and/or check writing privileges. The charges associated with the credit accessed are paid back to the pensioner, thereby retaining certain tax deferred privileges while permitting access to the accumulated funds.

TIM3に対する抗体およびその使用

Nº publicación: JP2026035570A 04/03/2026

Applicant:

ブリストル-マイヤーズスクイブカンパニー

JP_2026035570_A

Absstract of: EP1000000A1

The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.

traducir